SEARCH:   Advanced

Blood, 15 December 2007, Vol. 110, No. 13, pp. 4172-4174. Prepublished online as a Blood First Edition Paper on October 1, 2007; DOI 10.1182/blood-2007-07-104091. This Article Full Text (PDF) All Versions of this Article: blood-2007-07-104091v1 110/13/4172    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Elliott, M. A. Articles by Tallman, M. S Search for Related Content PubMed PubMed Citation Articles by Elliott, M. A. Articles by Tallman, M. S Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted July 31, 2007 Accepted September 17, 2007 Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival Michelle Ann Elliott*, Mark R. Litzow, Louis L Letendre, Robert C Wolf, Curtis A. Hanson, Ayalew Tefferi, and Martin S Tallman Division of Hematology/ Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States Pharmacy Services, Mayo Clinic, Rochester, MN, United States Department ofLaboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States Feinberg School of Medicine, Northwestern University, Chicago, IL, United States * Corresponding author; email: elliott.michelle{at}mayo.edu. In childhood acute lymphoblastic leukemia (ALL), a rapid decline of circulating leukemic blasts in response to induction chemotherapy or prednisone is one of the most important prognostic factors, not only for achieving remission, but also for relapse-free survival (RFS). However, in acute myeloid leukemia (AML) parameters of chemosensitivity have been restricted mainly to the rapidity of achievement of complete remission (CR) or the assessment of residual leukemic bone marrow blasts during aplasia. We hypothesized that the time to circulating peripheral blood blast clearance, as a potential surrogate for in-vivo chemosensitivity, would have prognostic relevance in AML also. In a retrospective analysis of a cohort of eighty-six adult patients with AML receiving uniform induction and consolidation chemotherapy, we demonstrate that the time to clearance of circulating blasts during induction chemotherapy is an independent prognostic marker of RFS, superseding other known or established risk factors, including karyotype and number of inductions to achieve CR. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Peripheral blood blast clearance during induction therapy in acute myeloid leukemia Giacomo Gianfaldoni, Francesco Mannelli, Sara Bencini, Franco Leoni, Simone Baldini, and Alberto Bosi Blood 2008 111: 1746-1747. [Full Text] [PDF] This article has been cited by other articles: G. Gianfaldoni, F. Mannelli, S. Bencini, F. Leoni, S. Baldini, and A. Bosi Peripheral blood blast clearance during induction therapy in acute myeloid leukemia Blood, February 1, 2008; 111(3): 1746 - 1747. [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020